natgillin/translations-raw huggingface dataset:
In the event of haemorrhagic complications, treatment must be discontinued and the source of bleeding investigated.
Pri zapletih zaradi krvavitve moramo zdravljenje prekiniti in ugotoviti njen izvor.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet i or the label to the physician.
V primeru stika osebe z zdravilno učinkovino cepiva, se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru stika osebe z učinkovino cepiva se naj takoj posvetuje z zdravnikom in mu pokaže navodila za uporabo ali nalepko.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leaflet or the label to the physician.
Če pride človek v stik z zdravilno učinkovino cepiva, se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko.
In the event of human exposure to the active ingredient of the vaccine, seek medical advice immediately and show the package leafletor the label to the physician.
V primeru stika osebe z zdravilno učinkovino cepiva se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko.
In the event of neurotoxicity, the recommended dose adjustment for ALIMTA and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov ALIMTE in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of neurotoxicity, the recommended dose adjustment for ALIMTA and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov zdravila ALIMTA in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Lilly and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov Pemetreksed Lilly in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Lilly and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov zdravila Pemetreksed Lilly in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of neurotoxicity, the recommended dose adjustment for Pemetrexed Sandoz and cisplatin is documented in Table 3.
Priporočene prilagoditve odmerkov Pemetrekseda Sandoz in cisplatina v primeru nevrološke toksičnosti so navedene v Preglednici 3.
In the event of overdosage there may be an increased risk of bleeding.
Pri prevelikem odmerjanju morda obstaja povečano tveganje za krvavitev.
In the event of overdose the patient should be observed and appropriate symptomatic treatment given.
V primeru prevelikega odmerjanja je treba bolnika opazovati in mu nuditi ustrezno podporno zdravljenje.
In the event of overdose, appropriate supportive treatment (possibly given parenterally) should be initiated according to the patient’s clinical signs and symptoms.
V primeru prevelikega odmerjanja je potrebno začeti z ustreznim podpornim zdravljenjem (če je mogoče, danim parenteralno) glede na bolnikove klinične znake in simptome.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
V primeru prevelikega odmerjanja je potrebno začeti z ustreznim podpornim zdravljenjem glede na bolnikove klinične znake in simptome.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
V primeru prevelikega odmerjanja je treba uvesti ustrezno podporno zdravljenje v skladu z bolnikovimi kliničnimi znaki in simptomi.
In the event of overdose, appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.
V primeru prevelikega odmerjanja je treba začeti ustrezno podporno zdravljenje glede na bolnikove klinične znake in simptome.
In the event of overdose, consider standard measures to remove unabsorbed active substance.
V primeru prevelikega odmerjanja je treba uporabiti standardne ukrepe za odstranitev neabsorbirane učinkovine.
In the event of overdose, ECG monitoring is recommended; standard supportive measures for managing QT prolongation should be adopted.
Pri prevelikem odmerjanju se priporoča spremljanje EKG-ja; uporabiti je treba standardne podporne ukrepe za obravnavanje podaljšanja intervala QT.
In the event of overdose, EMEND should be discontinued and general supportive treatment and monitoring should be provided.
V primeru prevelikega odmerjanja, je treba prekiniti zdravljenje z zdravilom EMEND ter bolniku nuditi splošno podporno zdravljenje in nadzor.
In the event of overdose, general supportive measures should be initiated based on the patient’s signs and symptoms.
Ob prevelikem odmerjanju se uvedejo podporni ukrepi na podlagi znakov in simptomov bolnice.
In the event of overdose, general supportive measures should be initiated based on the patient’s signs and symptoms.
V primeru prevelikega odmerka je treba uvesti splošne podporne ukrepe na podlagi bolničinih znakov in simptomov.
In the event of overdose, it is recommended that appropriate supportive treatment be initiated, as dictated by the patient’s clinical status, until resolution of the symptoms.
V primeru prevelikega odmerjanja je priporočeno začeti z ustreznim podpornim zdravljenjem v skladu z bolnikovim kliničnim stanjem, dokler simptomi niso odpravljeni.
In the event of overdose, symptomatic and supportive care is advised.
V primeru prevelikega odmerjanja se svetuje simptomatska in podporna nega.
In the event of progressive elevation, or clinically significant elevation in association with clinical features of myopathy or rhabdomyolysis, discontinuation of ziconotide should be considered.
V primeru progresivnega povečanja ali klinično signifikantnega povečanja v povezavi s klinično sliko miopatije ali rabdomiolize je potrebno razmisliti o ukinitvi zikonotida.
In the event of recurrence of
resnega neželenega učinka).
In the event of severe and persistent diarrhoea, Rasilamlo therapy should be stopped (see section 4.8).
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Rasilamlo prekiniti (glejte poglavje 4.8).
In the event of severe and persistent diarrhoea, Rasitrio therapy should be stopped (see section 4.8).
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Rasitrio prekiniti (glejte poglavje 4.8).
In the event of severe and persistent diarrhoea, Riprazo HCT therapy should be stopped.
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Riprazo HCT prekiniti.
In the event of severe and persistent diarrhoea, Sprimeo HCT therapy should be stopped.
V primeru hude ali persistentne driske je treba zdravljenje z zdravilom Sprimeo HCT prekiniti.
In the event of significant worsening, labile or treatment-resistant hypertension, interrupt treatment and consider evaluating for renal artery stenosis.
V primeru občutnega poslabšanja hipertenzije, labilne hipertenzije ali na zdravljenje odporne hipertenzije, prekinite zdravljenje in izvedite oceno stanja za stenozo ledvične arterije.
In the event of this happening treatment with Peyona should be stopped immediately and your baby’s doctor should treat the overdose.
V primeru, da se to zgodi, je treba zdravljenje z zdravilom Peyona takoj prekiniti, zdravnik pa mora začeti zdravljenje zaradi prevelikega odmerka.
In the event that a patient already receiving olaparib requires treatment with a P-gp inhibitor, careful monitoring of olaparib associated adverse events and management of those events via the dose reduction strategy is recommended (see section 4.2).
Če bolnica, ki že prejema olaparib, potrebuje zdravljenje z zaviralcem P-gp, jo je priporočljivo skrbno spremljati glede neželenih učinkov, povezanih z olaparibom, takšne učinke pa obvladovati z zmanjševanjem odmerka (glejte poglavje 4.2).
In the event that a patient already receiving olaparib requires treatment with a strong CYP3A inducer, the prescriber should be aware that the efficacy of olaparib may be substantially reduced (see section 4.5).
Če bolnik, ki že prejema olaparib, potrebuje zdravljenje z močnim induktorjem CYP3A, se mora zdravnik, ki predpisuje zdravilo, zavedati, da se lahko učinkovitost olapariba bistveno zmanjša (glejte poglavje 4.5).
In the event that co-administration of clofazimine with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended (see section 4.5).
Če je potrebna sočasna uporaba klofazimina in bedakilina je priporočeno klinično spremljanje, vključno s pogostim spremljanjem električne aktivnosti srca (elektrokardiogram) (glejte poglavje 4.5).
In the event that co-administration of such medicinal products with bedaquiline is necessary, clinical monitoring including frequent electrocardiogram assessment is recommended.
Če je sočasna uporaba teh zdravil z bedakilinom potrebna, je priporočeno klinično spremljanje, vključno s pogostim spremljanjem električne aktivnosti srca (elektrokardiogram).
In the event that commercially manufactured oseltamivir powder for oral suspension is not available, the pharmacist may compound a suspension (6 mg/ml) from Ebilfumin capsules or patients can prepare the suspension from capsules at home.
V primeru, da komercialno izdelanega oseltamivir praška za peroralno suspenzijo ni na voljo, lahko farmacevt pripravi suspenzijo (6 mg/ml) iz zdravila Ebilfumin kapsule ali bolnik pripravi suspenzijo iz kapsul doma.
In the event that serum calcium levels fall below 8.4 mg/dl (2.1 mmol/l) and/or symptoms of hypocalcaemia occur the following management is recommended:
Če se koncentracija kalcija v serumu zniža pod 8,4 mg/dl (2,1 mmol/l) in/ali se pojavijo simptomi hipokalciemije, je priporočljivo naslednje ukrepanje:
In the event that you have moderate or severe kidney problems, your doctor will reduce your dose to 400 mg once daily for moderate kidney problems and to 300 mg once daily for severe kidney problems.
Če imate zmerne ali hude težave z ledvicami, vam bo zdravnik zmanjšal odmerek na 400 mg enkrat na dan, če so vaše težave z ledvicami zmerne, ali na 300 mg enkrat na dan, če so vaše težave z ledvicami hude.
In the event-triggered analysis, vaccine efficacy against CIN1 associated with HPV 16/18 observed in the ATP cohort was 94.1% (96.1% CI: 83.4;98.5).
V analizi, proženi z dogodki, je bila učinkovitost cepiva proti CIN1, povezanemu s HPV 16/18, ugotovljena v kohorti PP, 94,1 % (96,1 % IZ: 83,4;98,5).
In the every 4 week dosing study, 113 of 458 patients (24.7%) treated with 300 mg every 4 weeks/150 mg every 2 weeks had two consecutive calculated LDL-C values <25 mg/dL (<0.65 mmol/L), and 45 of 458 patients (9.8%) had two consecutive calculated LDL-C values <15 mg/dL (<0.39 mmol/L).
V študiji uporabe na 4 tedne je imelo dve zaporedni izračunani vrednosti LDL-H < 25 mg/dl (< 0,65 mmol/l) 113 od 458 bolnikov (24,7 %), zdravljenih s 300 mg na 4 tedne/150 mg na 2 tedna, dve zaporedni izračunani vrednosti LDL-H < 15 mg/dl (< 0,39 mmol/l) pa 45 od 458 bolnikov (9,8 %).
In the example above the dose number shows there are 13 injections left
V zgornjem primeru število odmerkov kaže, da je preostalo še 13 injiciranj.
In the extension phase of these studies, which lasted up to 52 weeks, there was an increase in HbA1c in both the duloxetine and routine care groups, but the mean increase was 0.3% greater in the duloxetine- treated group.
V podaljšani fazi teh študij, ki je trajala do 52 tednov, se je vrednost HbA1c zvišala tako v skupini z duloksetinom kot v skupini bolnikov, ki so prejemali rutinsko oskrbo, vendar je bilo srednje zvišanje v skupini, zdravljeni z duloksetinom, večje za 0,3 %.
In the eye, prostaglandins increase the
Prostaglandin v očesu poveča
In the Eylea group the proportion of perfused patients was maintained through week 52).
V skupini, ki je prejemala zdravilo Eylea se je delež perfundiranih bolnikov ohranil do 52. tedna.
In the fasted state there was no significant difference in the extent of absorption, as measured by the area under the plasma concentration-time curve (AUC) and maximal peak concentration (Cmax), of each component.
Na osnovi površine pod krivuljo plazemske koncentracije v odvisnosti od časa (AUC) in največje koncentracije (Cmax) je bilo ugotovljeno, da na tešče ni pomembne razlike v obsegu absorpcije vsake izmed učinkovin.
In the female and black subgroups which represented 32 % and 26 % of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
V podskupinah z ženskami in temnopoltimi, ki so predstavljale 32 % oziroma 26 % celotne preiskovane populacije, ni bila dokazana koristnost irbesartana za ledvice, čeprav je meje zaupanja ne izključujejo.
In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
V podskupinah z ženskami in temnopoltimi, ki so predstavljale 32% oziroma 26% celotne preiskovane populacije, ni bila dokazana koristnost irbesartana za ledvice, čeprav je meje zaupanja ne izključuje jo.
In the female and black subgroups which represented 32% and 26% of the overall study population respectively, a renal benefit was not evident, although the confidence intervals do not exclude it.
V podskupinah z ženskami in temnopoltimi, ki so predstavljale 32% oziroma 26% celotne preiskovane populacije, ni bila dokazana koristnost irbesartana za ledvice, čeprav je meje zaupanja ne izključujejo.
In the field study 98.5% of vaccinated cattle sampled (range 269–274 animals) developed antibodies to both BVD virus types.
V terenski študiji je 98,5 % cepljenega goveda, zajetega v vzorec (razpon 269– 274 živali), razvilo protitelesa proti obema tipoma virusa goveje virusne diareje.
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses.
V terenski študiji osnovnega cepljenja je bilo ugotovljeno povečanje protiteles proti herpesvirusu rinotraheitisa mačk, okužbam s kalicivirusi in virusom panleukopenije mačk.
In the field study of basic vaccination there was an increase in antibodies against feline rhinotracheitis herpesvirus, calicivirus infection, and feline panleucopenia viruses.
V terenski študiji osnovnega cepljenja so ugotovili zvišanje ravni protiteles proti herpesvirusu rinotraheitisa mačk, kalicivirusu ter virusu panlevkopenije mačk.
In the FIELD study, a randomised placebo-controlled trial performed in 9795 patients with type 2 diabetes mellitus, a statistically significant increase in pancreatitis cases was observed in patients receiving fenofibrate versus patients receiving placebo (0.8% versus 0.5%; p=0.031).
V študiji FIELD, randomiziranem, s placebom kontroliranem preskušanju, opravljenem pri 9795 bolnikih s sladkorno boleznijo tipa 2, so ugotovili statistično značilno povečanje števila primerov pankreatitisa pri bolnikih, ki so prejemali fenofibrat, v primerjavi z bolniki, ki so prejemali placebo (0,8 % v primerjavi z 0,5 %; p = 0,031).
In the FIELD study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% [32/4900 patients] in the placebo group versus 1.1% [53/4895 patients] in the fenofibrate group; p = 0.022) and a statistically non-significant increase in deep vein thromboses (placebo: 1.0% [48/4900 patients] versus fenofibrate 1.4% [67/4895 patients]; p=0.074).
V študiji FIELD so ugotovili statistično pomembno zvišanje pojavnosti pljučne embolije (0,7 % [32/4900 bolnikov] v skupini, ki je prejemala placebo, v primerjavi z 1,1 % [53/4895 bolnikov] v skupini, ki je prejemala fenofibrat; p = 0,022) in statistično neznačilno zvišanje pojavnosti globoke venske tromboze (1,0 % v skupini, ki je prejemala placebo [48/4900 bolnikov], v primerjavi z 1,4 % v skupini, ki je prejemala fenofibrat [67/4895 bolnikov]; p=0,074).
In the field the studies of Purevax RCP FeLV looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCP FeLV na terenu so preučevale osnovno shemo cepljenja (2 injekciji 3–4 tedne narazen) ter obnovitveno cepljenje (samo ena injekcija).
In the field, aggression has been uncommonly reported.
Na terenu so občasno poročali o agresivnosti.
In the field, the studies of Purevax RC looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RC na terenu so preverili osnovni cepilni program (2 injekciji 3–4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
In the field, the studies of Purevax RCCh looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCCh na terenu so preverili osnovni cepilni program (2 injekciji 3–4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
In the field, the studies of Purevax RCP looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCP na terenu so preverili osnovni cepilni program (2 injekciji 3–4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
In the field, the studies of Purevax RCPCh FeLV looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and the booster vaccination (only one injection).
V študijah zdravila Purevax RCPCh FeLV na terenu so preučevali osnovno shemo cepljenja (2 injekciji 3–4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
In the field, the studies of Purevax RCPCh looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCPCh na terenu so preučevali osnovno shemo cepljenja (2 injekciji 3–4 tedne narazen) in obnovitveno cepljenje (samo ena injekcija).
In the fifth study, 526 of the 793 patients were ‘high need’, since they had failed to respond to or could not take other systemic treatments.
V peti raziskavi je bilo 526 izmed 793 bolnikov takih z „visoko potrebo“, saj se niso odzvali na ali niso mogli jemati drugih sistemskih zdravil.
In the fifth study, patients with wild-type KRAS in their tumours who received Vectibix on its own but in addition to best supportive care lived for an average of 16.0 weeks without their disease getting worse.
V peti študiji so bolniki z divjim genom KRAS v tumorjih, ki so prejemali zdravilo Vectibix poleg najboljše podporne nege, brez poslabšanja bolezni v povprečju živeli 16,0 tedna.
In the fifth week, your doctor will administer an intravenous infusion of diluted Soliris at a dose of 900 mg (3 vials of 30 ml) over a 25 – 45 minute period.
Peti teden vam bo zdravnik dal intravensko infuzijo razredčenega zdravila Soliris v odmerku 900 mg (3 viale po 30 ml), ki bo trajala 25 – 45 minut.
In the first and second studies, dyspnoea was reported as an adverse reaction following Rapiscan dosing (61% for patients with COPD; 34% for patients with asthma) while no subjects experienced dyspnoea following placebo dosing.
V prvi in drugi študiji so poročali o dispneji kot o neželenem učinku po dajanju zdravila Rapiscan (61% za bolnike s KOPB; 34% za bolnike z astmo), pri bolnikih, ki so prejeli placebo, pa ni bilo primerov dispneje.
In the first cycle, the initial dose was 9 mcg/day for week 1, then 28 mcg/day for the remaining 3 weeks.
Med prvim ciklusom je bil začetni odmerek 9 mcg/dan 1. teden, nato 28 mcg/dan preostale 3 tedne.
In the first few weeks after vaccination with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics the results of these tests may not be correct.
V prvih tednih po cepljenju s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics so lahko rezultati testov napačni.
In the first field study a group of 18-day-old embryonated eggs and a group of one-day-old chicks were vaccinated with Vectormune ND.
V prvi terenski študiji so s cepivom Vectormune ND cepili skupino 18 dni starih jajc z zarodki in skupino en dan starih piščancev.
In the first HL study, and in the sALCL study, both involving patients whose disease had already come back or not responded, the main measure of effectiveness was the percentage of patients who responded completely or partially to treatment.
V prvi študiji Hodgkinovega limfoma in v študiji sALCL, v katerih so sodelovali bolniki, katerih bolezen se je že ponovila ali se na zdravljenje niso odzvali, je bilo glavno merilo učinkovitosti odstotek bolnikov, pri katerih je bil odziv na zdravljenje popoln ali delen.
In the first ITP study, 59% of the patients who took Revolade (43 out of 73) had a platelet count of at least 50,000 per microlitre after six weeks, compared with 16% of those who took placebo (6 out of 37).
V prvi študiji pri bolnikih z imunsko trombocitopenično purpuro je bilo pri 59 % (43 od 73) bolnikov, ki so jemali zdravilo Revolade, po šestih tednih število trombocitov najmanj 50 000 na mikroliter v primerjavi s 16 % (6 od 37) bolnikov, ki so jemali placebo.
In the first line of the table the volume of your pen is already recorded for you (4).
V prvi vrstici preglednice je že zabeležen volumen injekcijskega peresnika (4).
In the first long-term study, a reduction in Y-MRS score of 12.9 was seen in patients taking Sycrest compared with 16.2 in patients taking olanzapine.
V prvi dolgotrajni študiji so pri bolnikih, ki so jemali zdravilo Sycrest, zabeležili zmanjšanje za
In the first main study, 57% of patients receiving Cimzia (141 out of 246) achieved 20% reductions compared with 9% of patients receiving placebo (11 out of 127).
V prvi glavni študiji je do 20-odstotnega zmanjšanja prišlo pri 57 % (141 od 246) bolnikov, ki so prejemali zdravilo Cimzia, v primerjavi z 9 % (11 od 127) bolnikov, ki so prejemali placebo.
In the first of the long-term studies, there was no difference between Thymanax and placebo in preventing symptoms from returning during 26 weeks of treatment.
V prvi dolgotrajni študiji ni bilo razlik med zdravilom Thymanax in placebom pri preprečevanju ponovnega pojava simptomov v 26 tednih zdravljenja.
In the first of the long-term studies, there was no difference between Valdoxan and placebo in preventing symptoms from returning during 26 weeks of treatment.
V prvi dolgotrajni študiji ni bilo razlik med zdravilom Valdoxan in placebom pri preprečevanju ponovnega pojava simptomov v 26 tednih zdravljenja.
In the first of these studies, the main measure of effectiveness was the number of women who had new fractures of the spine over three years.
Glavno merilo učinkovitosti v prvi študiji je bilo število žensk, pri katerih je v treh letih prišlo do novega zloma hrbtenice.
In the first part of the second study, around 45% of the patients who were taking steroids at the beginning of the study were able to reduce their dose of steroids (57 out of 128).
V prvem delu druge študije je lahko 45 % (57 od 128) bolnikov, ki so na začetku študije jemali steroide, odmerek steroidov zmanjšalo.
In the first short- term study, the reductions in Y-MRS score after three weeks were 11.5 and 14.6 points for Sycrest and olanzapine, respectively, compared with 7.8 points for placebo.
V prvi kratkotrajni študiji so se rezultati na lestvici Y-MRS po treh tednih zmanjšali za 11,5 oziroma
In the first short-term study, patients taking placebo had an average fall in their symptom score of 4.1 points, compared with an average fall of between 17.9 and 23.3 points in those taking Invega and of 19.9 in those taking olanzapine.
V prvi kratkoročni študiji se je bolnikom, ki so jemali placebo, rezultat vrednotenja simptomov v povprečju znižal za 4,1 točke v primerjavi s povprečnim znižanjem za 17,9 do 23,3 točke pri tistih, ki so jemali zdravilo Invega, in za 19,9 točke pri tistih, ki so jemali olanzapin.